Given the intricate interplay between STING and other molecular adaptors, strategies to inhibit STING in systemic lupus erythematosus (SLE) treatment must be meticulously crafted to optimize efficacy and minimize adverse effects. This evidence concerns the gene STING1 and systemic lupus erythematosus.